Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent form (ICF)~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Male or female, aged \>=18 years~* Diagnosed with active UC for at least 3 months prior to screening~* Total Mayo score \>=5 and Endoscopic sub-score \>=1~* Stable dosing regimens of oral drugs (if currently administered) as follows: 5-ASA or sulfasalazine at a stable dose for at least 4 weeks, purine analogues (azathioprine, mercaptopurine, thiopurines) or methotrexate at a stable dose for at least 12 weeks, and low-dose oral corticosteroid (up to 20 mg prednisone/day or equivalent) for at least 4 weeks prior to the first dose of study treatment. Doses of oral drugs must remain stable until the end of study treatment (with possible exception for tapering steroid dose after 8 weeks)~* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 3 months after the last dose~* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 3 months after the last dose~Exclusion Criteria:~* Use of anti-TNF-a biologics or any other biologics for treatment of UC within 60 days prior to randomization.~* Any rectal therapy for treatment of UC or intravenous corticosteroids within 2 weeks prior to randomization.~* Presence of Crohn's disease, indeterminate colitis, ischemic colitis, fulminant colitis, ulcerative proctitis, or toxic mega-colon~* Previous extensive colonic resection (subtotal or total colectomy)~* Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine~* Evidence of or treatment for Clostridium difficile infection or other pathogenic bowel infection within 60 days or for another intestinal pathogen within 30 days prior to randomization~* Active infection with the HIV or Hepatitis B or C viruses~* Clinically significant active extra-intestinal infection (e.g., pneumonia, pyelonephritis)~* Clinically significant abnormal vital signs, physical examination or 12-lead electrocardiogram (ECG) at screening or baseline~* Clinically significant abnormal results of liver function tests (ALT/AST, bilirubin and alkaline phosphatase) \> 2X the upper limit of normal (ULN) at screening~* Other clinically significant abnormal laboratory results at screening in the investigator's opinion~* History of any clinically significant medical condition that, in the investigator's opinion, would preclude participation in the study~* Pregnancy or lactation~* Treatment with another investigational drug or other intervention within 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BBT-401-1S (Type: EXPERIMENTAL): BBT-401-1S, Oral capsule, QD
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, Oral capsule, QD

Based on this trial design, predict the completion outcome and termination type (if applicable).